靶向CD13和TIM3的双特异性与分裂型CAR-T细胞清除急性髓系白血病
研究开发了STAR系统快速分离优先结合AML细胞的纳米抗体,其中Nb157特异性结合CD13,CD13 CAR-T在体外和体内有效清除AML。CD13与TIM3双特异性CAR-T清除了患者来源的AML,且在小鼠模型中对人骨髓干细胞和外周髓系细胞毒性显著降低,为AML CAR-T治疗提供了有前景的方法。
要点
- STAR系统可快速分离优先结合AML细胞的纳米抗体。
- CD13 CAR-T在体外和体内有效清除AML。
- CD13/TIM3双特异性CAR-T清除患者来源AML且骨髓毒性降低。
核心结论
- 靶向CD13和TIM3的双特异性CAR-T细胞可清除AML并对正常骨髓细胞毒性降低。
研究设计与样本
- 研究开发STAR系统分离纳米抗体并构建CD13及CD13/TIM3双特异性CAR-T,在体外和小鼠模型中进行功能验证。
主要发现
- Nb157特异性结合CD13,CD13 CAR-T在体外和体内有效清除AML。
- CD13/TIM3双特异性CAR-T清除患者来源AML,且对小鼠模型中人骨髓干细胞和外周髓系细胞毒性显著降低。
临床怎么用
- 提示CD13和TIM3双靶点CAR-T可能成为AML治疗的有前景策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells have radically improved the treatment of B cell-derived malignancies by targeting CD19. The success has not yet expanded to treat acute myeloid leukemia (AML). We developed a Sequentially Tumor-Selected Antibody and Antigen Retrieval (STAR) system to rapidly isolate multiple nanobodies (Nbs) that preferentially bind AML cells and empower CAR T cells with anti-AML efficacy. STAR-isolated Nb157 specifically bound CD13, which is highly expressed in AML cells, and CD13 CAR T cells potently eliminated AML in vitro and in vivo. CAR T cells bispecific for CD13 and TIM3, which are upregulated in AML leukemia stem cells, eradicated patient-derived AML, with much reduced toxicity to human bone marrow stem cells and peripheral myeloid cells in mouse models, highlighting a promising approach for developing effective AML CAR T cell therapy.
引用
- He X, Feng Z, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020. PMID: 31951650. doi:10.1182/blood.2019002779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。